• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Pasatru’s Rare Disease Approval With Home Infusion Potential Altering The Investment Case For Regeneron Pharmaceuticals (REGN)?

    Simply Wall St·08/31/2026 23:17:47
    Listen to the news
    • Regeneron Pharmaceuticals has secured past FDA approval for Pasatru (garetosmab-grts), a VelocImmune-derived monoclonal antibody that reduces new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva, based on Phase 3 OPTIMA trial data.
    • This approval introduces a new rare disease therapy that can be infused monthly, including in home settings, and is supported by strong lesion-reduction outcomes against placebo while carrying specific safety and pregnancy-related precautions.
    • We’ll now explore how Pasatru’s entry as a rare disease therapy with home-infusion potential may influence Regeneron’s broader investment narrative.

    AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Regeneron Pharmaceuticals Investment Narrative Recap

    To own Regeneron, you generally need to believe its high R&D spending will keep turning into new, meaningful therapies as EYLEA faces competition and pricing pressure. Pasatru’s FOP approval reinforces that innovation story, but it is unlikely to change the near term focus on ophthalmology, where EYLEA and EYLEA HD remain the key swing factors and risks to revenue and margins.

    Among recent developments, the April 2026 FDA decision to extend EYLEA HD dosing intervals up to 20 weeks in wAMD and DME looks especially relevant. That label update aims to make the ophthalmology franchise more resilient against branded and biosimilar anti VEGF rivals, which matters far more to Regeneron’s short term earnings profile than Pasatru’s contribution, even as Pasatru adds a differentiated rare disease therapy to the portfolio.

    Yet against this progress, investors should also be aware of the growing pressure from lower cost ophthalmology alternatives and how that could eventually affect...

    Read the full narrative on Regeneron Pharmaceuticals (it's free!)

    Regeneron Pharmaceuticals' narrative projects $19.4 billion revenue and $6.0 billion earnings by 2029. This requires 9.2% yearly revenue growth and about a $1.6 billion earnings increase from $4.4 billion today.

    Uncover how Regeneron Pharmaceuticals' forecasts yield a $833.31 fair value, a 4% upside to its current price.

    Exploring Other Perspectives

    REGN 1-Year Stock Price Chart
    REGN 1-Year Stock Price Chart

    Some of the lowest estimating analysts were already cautious, assuming only about 5.7% annual revenue growth to roughly US$18.3 billion by 2029, and the Pasatru approval could eventually test whether that more pessimistic view on pricing pressure and competition is still reasonable or needs to be revisited.

    Explore 6 other fair value estimates on Regeneron Pharmaceuticals - why the stock might be worth 9% less than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Regeneron Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
    • Our free Regeneron Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Regeneron Pharmaceuticals' overall financial health at a glance.

    Curious About Other Options?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.